Beranda › Skizofrenia › Illinois
Uji klinis Skizofrenia di Illinois
26 studi untuk Skizofrenia mencari peserta di lokasi di Illinois.
Kota di Illinois
Teks studi resmi (Bahasa Inggris)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- The University of Chicago, Chicago
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
Menerima pesertaFase 1
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
Menerima pesertaFase 3
Usia 5 hingga 17 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07114874A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Menerima pesertaFase 3
Usia 5 hingga 17 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
Menerima pesertaFase 2
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Menerima pesertaFase 3
Usia 13 hingga 17 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
Menerima pesertaFase 1
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
Menerima pesertaFase 3
Usia 10 hingga 17 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
Menerima pesertaStudi observasional
Usia 18 hingga 40 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
Menerima pesertaFase 2
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
Menerima pesertaFase 4
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
Menerima pesertaFase 4
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 11 Mei 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
Menerima pesertaStudi observasional
Usia 18 hingga 40 · Semua jenis kelamin · Diperbarui 10 Mar 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 6 Mar 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
Menerima pesertaFase 2
Usia 21 hingga 55 · Semua jenis kelamin · Diperbarui 26 Des 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 19 Des 2024 · NCT05184335Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.